Pharmacokinetic Evaluation of AMX0035 in Subjects with Renal Impairment and Healthy Controls

The primary objective of this study is to evaluate the **pharmacokinetics** of AMX0035 in participants with impaired renal function compared to healthy participants. This is clinically relevant as it aims to understand how renal impairment affects the absorption, distribution, metabolism, and excretion of AMX0035, which is crucial for determining appropriate dosing regimens and ensuring safety and efficacy in this population.

The clinical trial involves **volunteers with renal impairment** as well as healthy volunteers. The study population includes both male and female participants, with an age range that spans from young adults to older adults. The trial does not specifically target a vulnerable population. The sponsor has not provided information regarding the total number of participants. Participants were selected based on their health status, with a focus on those with renal impairment and those who are healthy. No specific lifestyle considerations such as diet, physical activity, or habits have been highlighted as part of the selection criteria. The sponsor has not disclosed any key inclusion or exclusion criteria for this trial.

The clinical trial is designed as a **Phase 3** study to evaluate the pharmacokinetics of AMX0035 in participants with **renal impairment** and healthy volunteers. The trial employs a randomized, double-blind, and controlled methodology to ensure the reliability and validity of the results. The estimated duration of the trial spans from August 1, 2023, to March 17, 2024, encompassing both the recruitment and study phases.

Participants will undergo a series of study visits, beginning with an inclusion visit, also known as the screening visit, to assess eligibility based on predefined criteria. This initial visit will involve comprehensive medical evaluations to confirm the participant's health status and suitability for the trial. Following successful screening, participants will be randomized into study groups and will attend multiple follow-up visits. These visits are scheduled to monitor the pharmacokinetic parameters of AMX0035, assess safety, and document any adverse events. The end-of-study visit will conclude the participant's involvement, during which final assessments will be conducted to gather data on the long-term effects of the treatment.

The expected length of participant involvement is approximately seven months, aligning with the overall trial duration. However, certain conditions may necessitate early termination from the study, such as the occurrence of significant adverse events, non-compliance with study protocols, or withdrawal of consent by the participant. The trial is structured to ensure that all procedures adhere to ethical standards and regulatory requirements, maintaining the integrity of the research and the safety of the participants.

The clinical trial involves the administration of an **experimental medication**. However, specific details regarding the name, pharmaceutical form, dosage, route, and frequency of administration are not provided in the available data. The trial documentation does not specify whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. Additionally, there is no information on the maximum daily dose, total dose, or treatment period for the experimental medication.

In this study, there is no mention of any **non-experimental treatments** such as standard-of-care therapy, placebo, or comparator treatment being used. The absence of these details suggests that the focus is primarily on the experimental medication, although further information would be required to confirm this aspect of the trial design.

Details regarding the **participant compliance monitoring** and any specific dosing schedules are not included in the provided data. The lack of such information indicates that additional documentation would be necessary to fully understand the administration and monitoring protocols within this clinical trial.

The clinical trial is in Phase 3 and is scheduled to have an estimated recruitment start date of August 1, 2023, with an estimated end date of March 17, 2024. The efficacy of the investigational treatment will be assessed through a structured evaluation process. The trial will involve the collection and analysis of data at predetermined timepoints throughout the study duration. The specific parameters or endpoints used to evaluate efficacy have not been detailed in the provided information. The trial will adhere to rigorous scientific standards to ensure the reliability and validity of the efficacy assessments. The methods and tools for measuring and analyzing efficacy will be aligned with the clinical trial protocols and technical documentation standards.